Cancer Pain Single Nucleotide Polymorphisms (SNPs)
- Conditions
- CancerPain
- Registration Number
- NCT00956878
- Lead Sponsor
- Erasmus Medical Center
- Brief Summary
Cancer pain is common in advanced cancer patients. Opioids are the mainstay of treatment in cancer pain. Responsiveness to and tolerability of opioids is, amongst others, determined by small variations in human DNA. Using blood samples from clinically well-defined cancer pain patients, the investigators are going to analyze single nucleotide polymorphisms (SNPs) in genes that are known to be involved in responsiveness to opioids and sensitivity to pain.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 243
- Cancer pain patients
- Patients not able to provide informed consent
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method correlation between pain SNPs and equianalgesic opioid requirement timepoint at blood sample candidate SNP analysis
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Erasmus MC, Centrumlocatie en Daniel den Hoed
🇳🇱Rotterdam, Zuid-Holland, Netherlands